哌拉西林钠/他唑巴坦在老年脑卒中急性期肺部感染中的应用

Clinical value of piperacillin/tazobactam in treatment of pulmonary infections during acute-stage stoke among elderly

目的:评价哌拉西林钠/他唑巴坦治疗老年脑卒中急性期中、重度肺部感染的临床疗效及安全性。方法:回顾性分析2010年4月至2011年4月辽宁省沈阳市红十字会医院收治的76例老年脑卒中急性期中、重度肺部感染患者的临床资料,按治疗方式不同分为观察组(40例)和对照组(36例),观察组给予哌拉西林钠/他唑巴坦钠4.5g静脉滴注,2次/d;对照组给予头孢唑肟3 g静脉滴注,2次/d,疗程10～14 d,2周后观察两组患者的临床疗效、细菌清除率等。结果:观察组与对照组总有效率、治愈率分别为为90%、72%与72%、50%,两组比较,差异有统计学意义(P<0.05)。观察组与对照组细菌清除率分别为80%与56%,两组比较差异有统计学意义(P<0.05)。结论:哌拉西林钠/他唑巴坦安全、抗菌谱广,在老年脑卒中急性期中、重度肺部感染治疗中疗效显著,值得推荐使用。

Objective：To evaluate the clinical efficacy and safety of Pipercillin/tazobactam in treatment of moderate to severe pulmonary infections during acute-stage stoke among elder patients, nethods：A retrospective analysis of clinical data was conducted in 76 patients with moderate to severe pulmonary infections during acute- stroke among elder patients who were admitted in our hospital between April 2010 to April 2011. The patients were randomly divided into the observation group （40 cases） and control group （36 cases）. The observation group was treated with intravenous piperacillin/tazobactam （4.5 g） every 12 h, and the control group treated with intravenous ceftizoxime （3 g）, for a duration of 10 to 14 days. The clinical efficacy and bacteria clearance rate were compared between the two groups after 2-week treatment. Results： The overall rates of response and recovery were 90% vs 72%, and 72% vs 50%, respectively, in the observation vs control group, with significant differences between the two groups （ P 〈 0. 05 ）. The rate of bacteria clearance was 80% vs 56% in the observation vs control group, with significant difference between the two groups （ P 〈 0.05 ）. Conclusion： piperaciUin/tazobactam is effective and safe for treatment of moderate to severe pulmonary infections during acutestage stroke in eider patients, and therefore warrants it widespread use in clinical practices.